33 results on '"Cahn, Avivit"'
Search Results
2. Dapagliflozin and prevention of kidney disease among patients with type 2 diabetes– post hoc analyses from the DECLARE-TIMI 58 trial
3. Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58.
4. Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
5. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
6. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
7. The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
8. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58
9. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
10. Targets for body fat, blood pressure, lipids, and glucose-lowering interventions in healthy older people
11. 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial
12. 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58
13. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
14. A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes.
15. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58.
16. 244-OR: Effects of Dapagliflozin on the Urinary Albumin-to-Creatinine Ratio in Patients with Type 2 Diabetes: A Predefined Analysis from the DECLARE-TIMI 58 Randomised, Placebo-Controlled Trial
17. 236-OR: Effects of Dapagliflozin on Progression of Diabetic Kidney Disease: Analysis from DECLARE-TIMI 58 Trial
18. Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study.
19. Feasibility of Creating a Diagnosis-Based Diabetic Foot Registry in a Large Health Care Provider
20. Use of a Machine Learning Algorithm Improves Prediction of Progression to Diabetes
21. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
22. Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1cTargets? Diabetes Care 2016;38:e145–e146
23. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
24. Clinical Considerations for Use of Initial Combination Therapy in Type 2 Diabetes
25. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS
26. Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
27. Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists
28. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease.
29. Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
30. Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial.
31. Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial.
32. Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146.
33. COMMENT ON SHAHRAZ ET AL. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? Diabetes Care 2016;38:e145-e146.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.